Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Equity (2022 - 2025)

Historic Return on Equity for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 0.67%.

  • BioXcel Therapeutics' Return on Equity fell 4300.0% to 0.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.67%, marking a year-over-year decrease of 4300.0%. This contributed to the annual value of 1.07% for FY2024, which is 187700.0% up from last year.
  • BioXcel Therapeutics' Return on Equity amounted to 0.67% in Q3 2025, which was down 4300.0% from 0.67% recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Return on Equity ranged from a high of 12.17% in Q3 2023 and a low of 6.89% during Q2 2023
  • Over the past 4 years, BioXcel Therapeutics' median Return on Equity value was 0.81% (recorded in 2024), while the average stood at 1.05%.
  • The largest annual percentage gain for BioXcel Therapeutics' Return on Equity in the last 5 years was 85300bps (2024), contrasted with its biggest fall of -110700bps (2024).
  • Over the past 4 years, BioXcel Therapeutics' Return on Equity (Quarter) stood at 1.62% in 2022, then soared by 328bps to 3.7% in 2023, then crashed by -76bps to 0.89% in 2024, then dropped by -25bps to 0.67% in 2025.
  • Its last three reported values are 0.67% in Q3 2025, 0.67% for Q2 2025, and 0.73% during Q1 2025.